The invention relates to the treatment of Charcot-Marie-Tooth disease with the progesterone receptor antagonist (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one and the pharmaceutically compatible salts thereof.本發明係關於使用孕酮受體拮抗劑(11β,17β)-17-羥基-11-[4-(甲磺醯基)苯基]-17-(五氟乙基)雌-4,9-二烯-3-酮及其醫藥學上相容的鹽治療恰克-馬利-杜斯氏症。